Boers Aniek, Arts Henriette J G, Klip Harry, Nijhuis Esther R, Pras Elisabeth, Hollema Harry, Wisman G Bea A, Nijman Hans W, Mourits Marian J E, Reyners Anna K L, de Bock Geertruida H, Thomas Gillian, van der Zee Ate G J
*Departments of Gynecologic Oncology, †Radiation Oncology, ‡Pathology, §Medical Oncology, and ∥Epidemiology, University of Groningen, University Medical Center Groningen, The Netherlands; and ¶Department of Radiation Oncology, University of Toronto, Ontario, Canada.
Int J Gynecol Cancer. 2014 Sep;24(7):1276-85. doi: 10.1097/IGC.0000000000000171.
The aim of this study was to determine possible impact of routinely scheduled biopsies and more radical surgery for residual central disease in locally advanced cervical cancer after (chemo)radiation.
METHODS/MATERIALS: Data were analyzed of a consecutive series of cervical cancer patients (The International Federation of Gynecology and Obstetrics stages IB1-IVA) treated with (chemo) radiation between 1994 and 2011. Patients underwent gynecologic examination with biopsies 8 to 10 weeks after treatment. Since 2001, larger biopsies by electric loop excision were taken, and more radical surgery (type III hysterectomy or exenteration) was performed for central residual disease. Primary outcome was locoregional recurrence. Secondary outcomes were treatment-associated morbidity and disease-specific survival.
Primary (chemo)radiation was given to 491 cervical cancer patients; 345 patients had a posttreatment biopsy. Viable tumor cells were identified in 84 patients, and 61 patients were eligible for salvage surgery. Residual disease after (chemo)radiation was an independent poor prognostic factor (hazard ratio, 3.59; 95% confidence interval, 2.18-5.93; P < 0.001). After 2001, larger biopsies were more frequently taken (29% vs 76%, P < 0.001), and in patients without viable tumor cells, locoregional recurrence after 2001 decreased from 21% to 10% (P = 0.01). After 2001, more patients underwent more radical surgery (46% vs 90%) (P < 0.001). Locoregional recurrence after surgery before 2001 occurred in 6 (46%) of the 13 patients, comparable with 19 (40%) of the 48 (P = 0.67) after 2001. More radical surgery was not associated with improved disease-specific survival (HR, 0.84; 95% CI, 0.20-3.46; P = 0.81) but did result in significantly more severe morbidity.
More radical surgery in patients with (minimal) central residual disease identified by routine biopsy 8 to 10 weeks after (chemo)radiation does not improve survival and should not be recommended.
本研究旨在确定在(化疗)放疗后,对局部晚期宫颈癌残留中心病灶进行定期活检及更激进手术的可能影响。
方法/材料:分析了1994年至2011年间接受(化疗)放疗的一系列连续宫颈癌患者(国际妇产科联盟分期为IB1-IVA期)的数据。患者在治疗后8至10周接受妇科检查并进行活检。自2001年起,采用电圈切除术进行更大范围的活检,并对中心残留病灶进行更激进的手术(III型子宫切除术或盆腔脏器清除术)。主要结局是局部区域复发。次要结局是治疗相关的发病率和疾病特异性生存率。
491例宫颈癌患者接受了初次(化疗)放疗;345例患者进行了治疗后活检。在84例患者中发现了存活的肿瘤细胞,61例患者符合挽救性手术的条件。(化疗)放疗后的残留病灶是一个独立的不良预后因素(风险比,3.59;95%置信区间,2.18-5.93;P<0.001)。2001年后,更大范围活检的比例更高(29%对76%,P<0.001),在没有存活肿瘤细胞的患者中,2001年后局部区域复发率从21%降至10%(P=0.01)。2001年后,更多患者接受了更激进的手术(46%对90%)(P<0.001)。2001年前手术患者的局部区域复发率在13例中有6例(46%),与2001年后48例中的19例(40%)相当(P=0.67)。更激进的手术与疾病特异性生存率的改善无关(风险比,0.84;95%置信区间,0.20-3.46;P=0.81),但确实导致更严重的发病率。
在(化疗)放疗后8至10周通过常规活检发现(微小)中心残留病灶的患者中,更激进的手术并不能提高生存率,不应被推荐。